^
    Back
    Association details:
    Biomarker:CD20 positive
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Rixathon (rituximab biosimilar) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    06/15/2017
    Excerpt:
    Rixathon is indicated for the treatment of patients with CD20 positive diffuse large B cell non Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
    Secondary therapy:
    CHOP
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    REFLECT real-world evidence (RWE) prospective study update: Efficacy and safety results of Sandoz biosimilar rituximab (SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL).

    Published date:
    05/25/2020
    Excerpt:
    REFLECT is the first prospective post-approval study to evaluate a rituximab biosimilar as a curative therapy in untreated pts with CD20+ DLBCL.... Summary of efficacy is reported in the Table....This interim analysis results re-confirms the expected safety and efficacy profile for DLBCL patients treated with R-CHOP.
    Secondary therapy:
    CHOP
    DOI:
    10.1200/JCO.2020.38.15_suppl.8060